Profusa, Inc. (PFSA) Key Metrics

NASDAQ: PFSAValuation, returns, debt and efficiency ratios over 5 years.

PFSA valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$563,917
Enterprise value
$14.5M
P/E (TTM)
0.0
Forward P/E
—
PEG ratio
—
Price / sales
104.7
Price / book
—
EV / EBITDA
—
Dividend yield
—
Beta
0.50

PFSA key metrics, 2021–2025

Fiscal year ended December 31, 2025 · U.S. dollars

PFSA valuation Price multiples at each fiscal year-end price.

Free cash flow yield
−24.6%
2025 · hover or tap a bar for each year
2022: −227.6%2023: −291.8% (−64.2 pts)2025: −24.6%
20212025

PFSA returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

PFSA debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

PFSA price vs earnings per share

Share price at year-endEPS (right axis)

PFSA key metrics

2021–2025
Profusa, Inc. key metrics by fiscal year
20252024202320222021
Valuation
Market capitalization$66.0M—$1.5M$3.4M—
Enterprise value$79.1M—$41.8M$34.3M—
Earnings yield−54.2%—−681.3%−597.5%—
Free cash flow yield−24.6%—−291.8%−227.6%—
Share price at fiscal year-end$197.25—$11.25$10.50—
Per share
Revenue per share$0.00—$0.00$0.00$0.00
Earnings per share−$107.01—−$76.65−$62.74−$31.99
Operating cash flow per share−$48.53—−$32.82−$23.90−$33.18
Free cash flow per share−$48.56—−$32.83−$23.90−$33.18
Cash per share$5.31—$1.06$0.24$2.66
Book value per share−$79.63—−$820.05−$309.61−$259.60
Tangible book value per share−$79.63—−$820.05−$309.61−$259.60
Capex per share$0.02—$0.01$0.00$0.00
Debt per share$44.25—$301.16$96.30$74.53
Shares outstanding335K—134K322K322K
Change in shares outstanding——−58.4%0.0%—
Returns & profitability
Return on assets (ROA)—−371.7%−703.2%−326.3%−90.7%
Return on tangible assets−949.0%−300.4%−543.1%—−90.7%
Financial health
Total debt$14.8M$48.2M$40.4M$31.0M$24.0M
Cash & short-term investments$1.8M$191,000$142,000$78,000$856,000
Net debt$13.0M$48.0M$40.3M$31.0M$23.2M
Debt / assets3.9215.6921.3430.102.11
Current ratio0.170.000.010.000.04
Quick ratio0.170.000.010.000.04
Interest coverage-2.6-1.0-1.4-1.8-2.9
Working capital−$18.5M−$56.9M−$46.4M−$35.5M−$20.7M
Invested capital−$13.6M−$71.2M−$69.7M−$68.8M−$60.5M
Tangible asset value−$26.7M−$119.2M−$110.0M−$99.8M−$83.7M
Net current asset value−$26.7M−$122.0M−$111.6M−$100.6M−$94.1M
Graham net-net per share−$85.60—−$832.85−$312.57−$292.11
Capital allocation
Capex / depreciation———0.000.00
Efficiency
Receivables turnover——0.000.000.00
Asset turnover0.000.000.000.000.00
Average receivables——$22,500$19,000$38,000
Average payables$6.1M$4.5M$3.7M$3.3M$3.3M
Intangibles / total assets0.0%0.0%0.0%0.0%0.0%

Computed from PFSA's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

PFSA valuation and financial ratios

Based on the latest twelve months, the trailing P/E is 0.0. It ended the year with $14.8 million of debt and $1.8 million in cash and short-term investments, net debt of $13.0 million. The share count rose 3.9% from 322K to 335K over 4 years.

See the PFSA income statement, the PFSA chart for price history, or the PFSA stock overview for the latest quote and news.

PFSA key metrics FAQ

What is Profusa's P/E ratio?

Profusa's trailing P/E ratio is 0.0 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was —.

How much debt does Profusa have?

Profusa had total debt of $14.8 million at the end of fiscal 2025.

What is Profusa's free cash flow yield?

Profusa generated -$16.3 million of free cash flow in fiscal 2025, a free cash flow yield of −24.6% on its market value at year-end ($66.0 million).

What is Profusa's current ratio?

Profusa's current ratio was 0.17 at the end of fiscal 2025: current assets were 0.17 times current liabilities.

Medical Devices key metrics